(Q37765620)

22 August 2017

1 reference

title

Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis (English)

1 reference

22 August 2017

0 references

1 reference

1 reference

Louise E Full

1

1 reference

22 August 2017

Claudia Monaco

series ordinal

2

1 reference

22 August 2017

publication date

14 June 2010

1 reference

Cardiovascular Therapeutics

22 August 2017

published in

1 reference

22 August 2017

volume

29

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

231-242

1 reference

The mortality of rheumatoid arthritis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Role of inflammation in atherosclerosis associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Role for TNF in atherosclerosis? Lessons from autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

The role of toll-like receptors in chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Targeting toll-like receptors for drug development: a summary of commercial approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Oxidation-specific epitopes are important targets of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Effect of glucocorticoids on the arteries in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

A novel anti-inflammatory role for simvastatin in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Anti-tumour necrosis factor agents and lipid profile: a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00159.X

10.1111/J.1755-5922.2010.00159.X

21 January 2018

Identifiers

DOI

1 reference

release_oy5vsedamjckvblb566v2st7im

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oy5vsedamjckvblb566v2st7im

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference